Aeterna Zentaris

Turing Pharmaceuticals launched

Wednesday, February 25, 2015

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

[Read More]

Aeterna Zentaris, Sinopharm A-Think ink agreement

Monday, December 1, 2014

Aeterna Zentaris, a specialty biopharmaceutical company based in Québec, and China-based Sinopharm A-Think Pharmaceuticals have signed of an exclusive license and technology transfer agreement for Aeterna Zentaris’ lead anti-cancer compound, zoptarelin doxorubicin, for the initial indication of endometrial cancer for the Chinese, Hong Kong and Macau markets (the territory). Zoptarelin doxorubicin, a novel synthetic peptide carrier linked to doxorubicin, currently is in a ZoptEC (zoptarelin doxorubicin in endometrial cancer) phase III trial in endometrial cancer.

[Read More]

Aeterna Zentaris to house business, commercial operations in Charleston, S.C.

Wednesday, May 7, 2014

Aeterna Zentaris, a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, has selected Charleston, S.C., for its North American business and global commercial operations. Over the next five years, Aeterna Zentaris will hire staff to support commercial operations, business development, regulatory and quality assurance, manufacturing management, clinical and product development, as well as various administrative functions. The Coordinating Council for Economic Development of South Carolina has approved job development credits to Aeterna Zentaris.

[Read More]

Aeterna Zentaris, Hikma partner in commericalization of Perifosine

Wednesday, November 23, 2011

Aeterna Zentaris and Hikma Pharmaceuticals have signed an exclusive commercialization and licensing agreement for the registration and marketing of perifosine, Aeterna Zentaris’ lead anti-cancer compound, for the MENA (Middle East and North Africa) region. Perifosine, a novel oral Akt inhibitor, is currently in two phase III programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe.

[Read More]